AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.050
+0.070 (2.35%)
At close: May 4, 2026, 4:00 PM EDT
3.020
-0.030 (-0.98%)
After-hours: May 4, 2026, 4:23 PM EDT
AC Immune Employees
As of December 31, 2025, AC Immune had 122 total employees, including 90 full-time and 32 part-time employees. The number of employees decreased by 50 or -29.07% compared to the previous year.
Employees
122
Change (1Y)
-50
Growth (1Y)
-29.07%
Revenue / Employee
$37,830
Profits / Employee
-$676,680
Market Cap
302.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | -50 | -29.07% | 90 | 32 |
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Abeona Therapeutics | 226 |
| LENZ Therapeutics | 152 |
| Zentalis Pharmaceuticals | 106 |
| Foghorn Therapeutics | 106 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Protara Therapeutics | 46 |
ACIU News
- 4 days ago - AC Immune First Quarter 2026 Financial and Corporate Updates - GlobeNewsWire
- 4 days ago - AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease - GlobeNewsWire
- 27 days ago - AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - GlobeNewsWire
- 7 weeks ago - AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 5 months ago - AC Immune Transcript: Study Update - Transcripts
- 5 months ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 5 months ago - AC Immune Transcript: Jefferies London Healthcare Conference 2025 - Transcripts